DK1448995T3 - Analyse til screening af lægemiddelkandidater til behandling af inflammatoriske sygdomme - Google Patents
Analyse til screening af lægemiddelkandidater til behandling af inflammatoriske sygdommeInfo
- Publication number
- DK1448995T3 DK1448995T3 DK02779724.0T DK02779724T DK1448995T3 DK 1448995 T3 DK1448995 T3 DK 1448995T3 DK 02779724 T DK02779724 T DK 02779724T DK 1448995 T3 DK1448995 T3 DK 1448995T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- candidate drug
- analysis
- inflammatory diseases
- drug candidates
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0127916.5A GB0127916D0 (en) | 2001-11-21 | 2001-11-21 | Method |
| PCT/GB2002/005255 WO2003046580A1 (en) | 2001-11-21 | 2002-11-20 | Assay for screening candidate drugs for the treatment of inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1448995T3 true DK1448995T3 (da) | 2011-05-16 |
Family
ID=9926193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02779724.0T DK1448995T3 (da) | 2001-11-21 | 2002-11-20 | Analyse til screening af lægemiddelkandidater til behandling af inflammatoriske sygdomme |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7998474B2 (da) |
| EP (1) | EP1448995B9 (da) |
| JP (2) | JP5362940B2 (da) |
| AT (1) | ATE496302T1 (da) |
| AU (1) | AU2002343063B2 (da) |
| CA (1) | CA2468082C (da) |
| DE (1) | DE60239009D1 (da) |
| DK (1) | DK1448995T3 (da) |
| ES (1) | ES2362494T3 (da) |
| GB (1) | GB0127916D0 (da) |
| WO (1) | WO2003046580A1 (da) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050390A1 (it) * | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
| US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| AU2008317000B2 (en) * | 2007-10-26 | 2014-10-23 | Brenda E. Moore | Probiotic compositions and methods for inducing and supporting weight loss |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| JP5715070B2 (ja) | 2009-02-16 | 2015-05-07 | ノグラ ファーマ リミテッド | アルキルアミド化合物およびその使用 |
| WO2012097207A2 (en) * | 2011-01-13 | 2012-07-19 | The Johns Hopkins University | Cytokine profiles as methods for diagnosis and prognosis of irritable bowel syndrome |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| US20130022575A1 (en) * | 2011-07-19 | 2013-01-24 | Microbial Rx | Systems and methods of replacing intestinal flora |
| GB201117313D0 (en) * | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| WO2013053836A1 (en) | 2011-10-11 | 2013-04-18 | Quantum Pharmaceuticals Sa | Composition comprising anaerobically cultivated human intestinal microbiota |
| JP6301844B2 (ja) | 2012-02-09 | 2018-03-28 | ノグラ ファーマ リミテッド | 線維症の処置方法 |
| CN109172816A (zh) | 2012-03-29 | 2019-01-11 | 塞拉拜姆有限责任公司 | 在回肠和阑尾上有活性的胃肠位点特异性口服接种疫苗制剂 |
| MX2014012652A (es) | 2012-04-18 | 2014-11-25 | Nogra Pharma Ltd | Metodo de tratamiento de la intolerancia a la lactosa. |
| US9814756B2 (en) | 2012-06-15 | 2017-11-14 | Temple University—Of the Commonwealth System of Higher Education | Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CN104546935A (zh) * | 2014-09-30 | 2015-04-29 | 深圳华大基因科技有限公司 | 多形拟杆菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
| NO3065748T3 (da) * | 2014-12-23 | 2018-04-21 | ||
| AU2018205072B2 (en) * | 2014-12-23 | 2020-05-21 | Cj Bioscience, Inc. | Immune modulation |
| SI3193901T1 (en) | 2014-12-23 | 2018-06-29 | 4D Pharma Research Limited | Pirin polypeptide and immune modulation |
| FR3035329A1 (fr) * | 2015-04-23 | 2016-10-28 | Agronomique Inst Nat Rech | La prevention ou le traitement d'une infection par bacteroides thetaiotaomicron |
| ME03563B (me) | 2015-06-15 | 2020-07-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| HUE044617T2 (hu) | 2015-06-15 | 2019-11-28 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
| SG10201912324XA (en) | 2015-06-15 | 2020-02-27 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| KR20180038414A (ko) * | 2015-08-17 | 2018-04-16 | 세키스이 메디칼 가부시키가이샤 | 면역학적 검출 방법 및 이것에 사용하는 테스트 스트립 |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| MD3209310T2 (ro) | 2015-11-20 | 2018-06-30 | 4D Pharma Res Ltd | Compoziții care conțin tulpini bacteriene |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN114712405A (zh) | 2016-03-04 | 2022-07-08 | 4D制药有限公司 | 包含细菌菌株的组合物 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| TWI782800B (zh) * | 2016-06-15 | 2022-11-01 | 英商4D製藥研究有限公司 | 包含菌株之組合物及其用途、製法及產品 |
| TWI750342B (zh) * | 2016-06-15 | 2021-12-21 | 英商4D製藥研究有限公司 | 包含菌株之組合物及其用途、製法及產品 |
| TWI621708B (zh) * | 2016-06-15 | 2018-04-21 | ４Ｄ製藥研究有限公司 | 免疫調節 |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| EP3630137B1 (en) | 2017-05-22 | 2023-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| MA41708A (fr) | 2017-05-24 | 2020-04-08 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| CA3066189A1 (en) | 2017-06-14 | 2018-12-20 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| PL3600364T3 (pl) | 2017-06-14 | 2021-01-11 | 4D Pharma Research Limited | Kompozycje zawierające szczep bakteryjny z rodzaju megasphaera i ich zastosowania |
| SI3638271T1 (sl) | 2017-06-14 | 2021-01-29 | 4D Pharma Research Limited | Sestavki, ki vsebujejo bakterijske seve |
| MA51614A (fr) | 2018-01-19 | 2021-04-28 | 4D Pharma Res Ltd | Polythérapie pour le traitement ou la prévention du cancer |
| JP2021516661A (ja) | 2018-01-19 | 2021-07-08 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | がんを処置または予防するための併用療法 |
| MX2020007671A (es) | 2018-01-19 | 2020-09-14 | 4D Pharma Res Limited | Terapia de combinacion para tratar o prevenir el cancer. |
| CA3088338A1 (en) | 2018-01-19 | 2019-07-25 | 4D Pharma Research Limited | Combination therapy for treating or preventing cancer |
| AU2019238358A1 (en) | 2018-03-19 | 2020-10-08 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| JP2021523895A (ja) | 2018-05-11 | 2021-09-09 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| JP2021526526A (ja) | 2018-06-14 | 2021-10-07 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| CA3103064A1 (en) | 2018-06-19 | 2019-12-26 | 4D Pharma Research Ltd | Dosage form comprising a live biotherapeutic product |
| WO2020002370A1 (en) | 2018-06-25 | 2020-01-02 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| CA3106139A1 (en) | 2018-07-16 | 2020-01-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW202023590A (zh) | 2018-08-17 | 2020-07-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| TW202023589A (zh) | 2018-09-20 | 2020-07-01 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
| MX2021004150A (es) * | 2018-10-09 | 2021-06-08 | 4D Pharma Res Limited | Composiciones que comprenden cepas bacterianas. |
| EP3866822A1 (en) | 2018-10-19 | 2021-08-25 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| JP2022512813A (ja) | 2018-11-02 | 2022-02-07 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| JP2022513790A (ja) | 2018-12-12 | 2022-02-09 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| TW202038977A (zh) | 2018-12-12 | 2020-11-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| MA54161A (fr) | 2018-12-12 | 2022-03-23 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes parabacteroides pour le traitement du cancer |
| BR112021015609A2 (pt) | 2019-02-08 | 2021-10-05 | Nogra Pharma Limited | Processo de fabricação de ácido 3-(4?-aminofenil)-2-metoxipropiônico, e análogos e intermediários do mesmo |
| EP3917550B1 (en) | 2019-05-10 | 2024-01-24 | CJ Bioscience, Inc. | Compositions comprising blautia hydrogenotrophica in the treatemnt of fibromyalgia |
| EP4066844A1 (en) | 2019-07-05 | 2022-10-05 | 4D Pharma Research Limited | Compositions comprising anaerostipes hadrus |
| JP2023503410A (ja) | 2019-11-20 | 2023-01-30 | フォーディー ファーマ リサーチ リミテッド | 細菌株を含む組成物 |
| EP3839039A1 (en) | 2019-12-16 | 2021-06-23 | 4D Pharma Research Limited | Providing bacterial biomass with improved storage stability |
| EP3838281A1 (en) | 2019-12-20 | 2021-06-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW202140773A (zh) | 2020-01-27 | 2021-11-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組成物 |
| TW202220639A (zh) | 2020-08-06 | 2022-06-01 | 英商４Ｄ製藥有限公司 | 凍乾方法 |
| AU2021386691A1 (en) | 2020-11-26 | 2023-07-06 | 4D Pharma Leon, S.L.U. | Process |
| JPWO2022191182A1 (da) * | 2021-03-08 | 2022-09-15 | ||
| US20230192904A1 (en) * | 2021-11-19 | 2023-06-22 | The Brigham And Women's Hospital, Inc. | Bifunctional chimeric molecules for labeling of kinases with target binding moieties and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443826A (en) * | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli |
| ATE165738T1 (de) | 1988-08-02 | 1998-05-15 | Gastro Services Pty Ltd | Behandlung von gastro-intestinalen krankheiten |
| US5039703A (en) * | 1989-11-16 | 1991-08-13 | Breuer Richard I | Method for treating inflammatory bowel disorders |
| US5599795A (en) * | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
| US6033864A (en) | 1996-04-12 | 2000-03-07 | The Regents Of The University Of California | Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens |
| GB9616047D0 (en) | 1996-07-31 | 1996-09-11 | Glaxo Group Ltd | Medicament carrier with agglomerated large medicament particles and related method of manufacture thereof |
| WO1998043081A1 (en) | 1997-03-26 | 1998-10-01 | Ligand Pharmaceuticals Incorporated | Treatment of gastrointestinal disease with ppar modulators |
| US5925657A (en) | 1997-06-18 | 1999-07-20 | The General Hospital Corporation | Use of PPARγ agonists for inhibition of inflammatory cytokine production |
| US5951977A (en) * | 1997-10-14 | 1999-09-14 | The United States Of America, As Represented By The Secretary Of Agriculture | Competitive exclusion culture for swine |
| WO2001016120A1 (en) | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| US6864355B1 (en) * | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| US20040062757A1 (en) * | 2001-06-05 | 2004-04-01 | Finegold Sydney M. | Method of testing gastrointestinal diseases associated with species of genus clostridium |
| AUPQ899700A0 (en) * | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| WO2002085123A1 (en) * | 2001-04-18 | 2002-10-31 | Merck & Co., Inc. | Ppar-alpha-gamma ligands or agonists for the treatment of inflammation |
-
2001
- 2001-11-21 GB GBGB0127916.5A patent/GB0127916D0/en not_active Ceased
-
2002
- 2002-10-31 US US10/285,224 patent/US7998474B2/en not_active Expired - Fee Related
- 2002-11-20 JP JP2003547968A patent/JP5362940B2/ja not_active Expired - Fee Related
- 2002-11-20 WO PCT/GB2002/005255 patent/WO2003046580A1/en active Application Filing
- 2002-11-20 CA CA2468082A patent/CA2468082C/en not_active Expired - Lifetime
- 2002-11-20 ES ES02779724T patent/ES2362494T3/es not_active Expired - Lifetime
- 2002-11-20 DE DE60239009T patent/DE60239009D1/de not_active Expired - Lifetime
- 2002-11-20 DK DK02779724.0T patent/DK1448995T3/da active
- 2002-11-20 AT AT02779724T patent/ATE496302T1/de not_active IP Right Cessation
- 2002-11-20 EP EP02779724A patent/EP1448995B9/en not_active Expired - Lifetime
- 2002-11-20 AU AU2002343063A patent/AU2002343063B2/en not_active Expired
-
2012
- 2012-09-06 JP JP2012196103A patent/JP2013046615A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5362940B2 (ja) | 2013-12-11 |
| JP2013046615A (ja) | 2013-03-07 |
| DE60239009D1 (de) | 2011-03-03 |
| CA2468082C (en) | 2012-06-26 |
| AU2002343063A1 (en) | 2003-06-10 |
| EP1448995B1 (en) | 2011-01-19 |
| GB0127916D0 (en) | 2002-01-16 |
| ES2362494T3 (es) | 2012-10-05 |
| ATE496302T1 (de) | 2011-02-15 |
| EP1448995B9 (en) | 2011-10-12 |
| CA2468082A1 (en) | 2003-06-05 |
| US20030133875A1 (en) | 2003-07-17 |
| WO2003046580A1 (en) | 2003-06-05 |
| EP1448995A1 (en) | 2004-08-25 |
| JP2005510733A (ja) | 2005-04-21 |
| AU2002343063B2 (en) | 2008-06-05 |
| US7998474B2 (en) | 2011-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1448995T3 (da) | Analyse til screening af lægemiddelkandidater til behandling af inflammatoriske sygdomme | |
| Orioli et al. | Epigenetic regulation of skin cells in natural aging and premature aging diseases | |
| Aschbacher et al. | Good stress, bad stress and oxidative stress: insights from anticipatory cortisol reactivity | |
| Staquet et al. | Different roles of odontoblasts and fibroblasts in immunity | |
| Liu et al. | Oxidized low-density lipoprotein increases the proliferation and migration of human coronary artery smooth muscle cells through the upregulation of osteopontin | |
| Lu et al. | Melatonin attenuates osteosarcoma cell invasion by suppression of C‐C motif chemokine ligand 24 through inhibition of the c‐Jun N‐terminal kinase pathway | |
| Oyagbemi et al. | Toxicological evaluations of methanolic extract of Moringa oleifera leaves in liver and kidney of male Wistar rats | |
| NO995543D0 (no) | Monoestere fra probucol for behandling av kardiovaskulaer og inflammatorisk sykdom | |
| Javed et al. | Cytokine profile in the gingival crevicular fluid of rheumatoid arthritis patients with chronic periodontitis | |
| CY1110271T1 (el) | Υδατικες παρατεταμενης-απελευθερωσης φαρμακοτεχνικες μορφες πρωτεϊνων | |
| Stoops et al. | Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells | |
| EA200100958A1 (ru) | Производные 4,5-диарил-3(2h)-фуранона как ингибиторы циклооксигеназы-2 | |
| EA201070738A1 (ru) | Композиции и способы детекции tiab | |
| NO20051024L (no) | Fremgangsmate for diagnostisering av multippel sklerose | |
| Kimura et al. | Histamine-release effectors from Angelica dahurica var. dahurica root | |
| Ma et al. | Synthesis and evaluation of bakuchiol derivatives as potent anti-inflammatory agents in vitro and in vivo | |
| Guergues et al. | Deep proteome profiling reveals novel pathways associated with pro-inflammatory and alcohol-induced microglial activation phenotypes | |
| Cai et al. | Histone H4R3 symmetric di-methylation by Prmt5 protects against cardiac hypertrophy via regulation of Filip1L/β-catenin | |
| NO20003868D0 (no) | Hydroksam- og karboksylsyrederivater | |
| Oh et al. | Capsazepine, a vanilloid receptor antagonist, inhibits the expression of inducible nitric oxide synthase gene in lipopolysaccharide-stimulated RAW264. 7 macrophages through the inactivation of nuclear transcription factor-kappa B | |
| Mormina et al. | Cannabinoid signalling in TNF-α induced IL-8 release | |
| Bam et al. | Long non-coding RNA LINC00926 regulates WNT10B signaling pathway thereby altering inflammatory gene expression in PTSD | |
| Song et al. | Stuttering interneurons generate fast and robust inhibition onto projection neurons with low capacity of short term modulation in mouse lateral amygdala | |
| Boule et al. | Summary of the 2016 alcohol and immunology research interest group (AIRIG) meeting | |
| Liu et al. | 3, 4-Methylenedioxymethamphetamine causes cytotoxicity on 661W cells through inducing macrophage polarization |